The relationship between oxytocin, vasopressin and atrial natriuretic peptide levels and cognitive functions in patients with schizophrenia

References

• Özgüven HD. Ruh Sağlığı ve Hastalıkları Ders Kitabı. Ankara: Ankara Üniversitesi Tıp Fakültesi Yayınları; 2014; [Mental Health and Diseases Textbook. Ankara: Ankara University Faculty of Medicine Publications; 2014].
   Google Scholar
• Palmer BW, Heaton RK, Paulsen JS, et al. Is it possible to be schizophrenic yet neuropsychologically normal? Neuropsychol. 1997;11:437–446. doi: 10.1037/0894-4105.11.3.437
   Google Scholar
• Harvey PD, Sharma T. Understanding and treating cognition in schizophrenia: a clinician’s handbook [Şizofrenide Kognisyonu Anlama ve Tedavisi Klinisyenin El Kitabı: editor Hüsnü Erkmen]. London: Martin Dunitz; 2002.
   Google Scholar
• Andreasen NC, Black DW. Introductory textbook of psychiatry. 3rd ed. Washington, DC: American Psychiatric; 2001.
   Google Scholar
• Bucci P, Galderisi S, Mucci A, et al. Premorbid academic and social functioning in patients with schizophrenia and its associations with negative symptoms and cognition. Acta Psychiatr Scand. 2018;138:253–266.
   Web of Science ®Google Scholar
• Tsoi DT, Lee KH, Khokhar WA, et al. Is facial emotion recognition impairment in schizophrenia identical for different emotions? A signal detection analysis. Schizophr Res. 2008;99:263–269. doi: 10.1016/j.schres.2007.11.006
   PubMed Web of Science ®Google Scholar
• Balikci K, Aydin O, Tas C, et al. Oxytocin and social cognition in patients with schizophrenia: comparison with healthy siblings and healthy controls. Psychiatry Clin Psychopharmacol. 2018;28:123–130. doi: 10.1080/24750573.2017.1387405
   Web of Science ®Google Scholar
• Heinrichs M, von Dawans B, Domes G. Oxytocin, vasopressin, and human social behavior. Front Neuroendocrinol. 2009;30:548–557. doi: 10.1016/j.yfrne.2009.05.005
   PubMed Web of Science ®Google Scholar
• Goldman M, Marlow-O’Connor M, Torres I, et al. Diminished plasma oxytocin in schizophrenic patients with neuroendocrine dysfunction and emotional deficits. Schizophr Res. 2008;98:247–255. doi: 10.1016/j.schres.2007.09.019
   PubMed Web of Science ®Google Scholar
• Keri S, Kiss I, Kelemen O. Sharing secrets: oxytocin and trust in schizophrenia. Soc Neurosci. 2009;4:287–293. doi: 10.1080/17470910802319710
   PubMed Web of Science ®Google Scholar
• Rosenfeld AJ, Lieberman JA, Jarskog LF. Oxytocin, dopamine, and the amygdala: a neurofunctional model of social cognitive deficits in schizophrenia. Schizophr Bull. 2011;37:1077–1087. doi: 10.1093/schbul/sbq015
   PubMed Web of Science ®Google Scholar
• Kosfeld M, Heinrichs M, Zak PJ, et al. Oxytocin increases trust in humans. Nat. 2005;435:673–676. doi: 10.1038/nature03701
   Google Scholar
• Macdonald K, Macdonald TM. The peptide that binds: a systematic review of oxytocin and its prosocial effects in humans. Harv Rev Psychiatry. 2010;18:1–21. doi: 10.3109/10673220903523615
   PubMed Web of Science ®Google Scholar
• Meyer-Lindenberg A, Tost H. Neural mechanisms of social risk for psychiatric disorders. Nat Neurosci. 2012;15:663–668. doi: 10.1038/nn.3083
   PubMed Web of Science ®Google Scholar
• Feifel D. Oxytocin as a potential therapeutic target for schizophrenia and other neuropsychiatric conditions. Neuropsychopharmacol. 2012;37:304–305. doi: 10.1038/npp.2011.184
   PubMed Web of Science ®Google Scholar
• Caldwell HK, Lee HJ, Macbeth AH, et al. Vasopressin: behavioral roles of an ‘original’ neuropeptide. Prog Neurobiol. 2008;84:1–24. doi: 10.1016/j.pneurobio.2007.10.007
   PubMed Web of Science ®Google Scholar
• Onaka T, Yagi K. Involvement of N-methyl-D-aspartic acid receptor activation in oxytocin and vasopressin release after osmotic stimuli in rats. J Neuroendocrinol. 2001;13:166–174. doi: 10.1046/j.1365-2826.2001.00607.x
   Web of Science ®Google Scholar
• Riggs AT, Dysken MW, Kim SW, et al. A review of disorders of water homeostasis in psychiatric patients. Psychosomatics. 1991;32:133–148. doi: 10.1016/S0033-3182(91)72084-7
   PubMed Web of Science ®Google Scholar
• Rubin LH, Li S, Yao L, et al. Peripheral oxytocin and vasopressin modulates regional brain activity differently in men and women with schizophrenia. Schizophr Res. 2018;202:173–179. doi:10.1016/j.schres.2018.07.003.
   Web of Science ®Google Scholar
• Kellner M, Wiedemann K, Holsboer F. Atrial natriuretic factor inhibits the CRH-stimulated secretion of ACTH and cortisol in man. Life Sci. 1992;50:1835–1842. doi: 10.1016/0024-3205(92)90543-X
   PubMed Web of Science ®Google Scholar
• Steardo L, Nathanson JA. Brain barrier tissues: end organs for atriopeptins. Sci. 1987;235:470–473. doi: 10.1126/science.2879355
   PubMed Web of Science ®Google Scholar
• Ibanez-Santos J, Tsagarakis S, Rees LH, et al. Atrial natriuretic peptides inhibit the release of corticotrophin-releasing factor-41 from the rat hypothalamus in vitro. J Endocrinol. 1990;126:223–228. doi: 10.1677/joe.0.1260223
   Web of Science ®Google Scholar
• Griebel G. Is there a future for neuropeptide receptor ligands in the treatment of anxiety disorders? Pharmacol Ther. 1999;82:1–61. doi: 10.1016/S0163-7258(98)00041-2
   PubMed Web of Science ®Google Scholar
• Langub Jr. MC, Watson Jr. RE, Herman JP. Distribution of natriuretic peptide precursor mRNAs in the rat brain. J Comp Neurol. 1995;356:183–199. doi: 10.1002/cne.903560205
   Web of Science ®Google Scholar
• Skofitsch G, Jacobowitz DM, Eskay RL, et al. Distribution of atrial natriuretic factor-like immunoreactive neurons in the rat brain. Neurosci. 1985;16:917–948. doi: 10.1016/0306-4522(85)90106-X
   PubMed Web of Science ®Google Scholar
• Kawata M, Nakao K, Morii N, et al. Atrial natriuretic polypeptide: topographical distribution in the rat brain by radioimmunoassay and immunohistochemistry. Neurosci. 1985;16:521–546. doi: 10.1016/0306-4522(85)90190-3
   PubMed Web of Science ®Google Scholar
• First MB, Spitzer RL, Gibbon M, et al. Structured clinical interview for DSM-IV clinical version (SCID-I/CV). Washington (DC): American Psychiatric Press; 1997.
   Google Scholar
• Özkürkçügil Corapcıoglu A, Aydemir Ö, Yıldız M, et al. DSM-IV Eksen I bozuklukları için yapılandırılmış klinik görüşmenin Türkçe’ye uyarlanması ve güvenilirlik çalışması [Turkish version of the structured clinical interview for DSM-IV axis I disorders and reliability study]. İlaç ve tedavi dergisi [J Med Treat]. 1999;12:233–236.
   Google Scholar
• Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261–276. doi: 10.1093/schbul/13.2.261
   PubMed Web of Science ®Google Scholar
• Guy W. ECDEU assessment manual for psychopharmacology. Rockville (MD): US Department of Heath, Education, and Welfare Public Health Service Alcohol, Drug Abuse, and Mental Health Administration; 1976.
   Google Scholar
• Amerikan Psikiyatri Birliği. Mental Bozuklukların Tanısal ve Sayımsal Elkitabı, Dördüncü Baskı (DSM-IV) [American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV)] Köroğlu E (çev.) Ankara; Hekimler Yayın Birliği [Ankara; Physicians Publication Association].1994.
   Google Scholar
• Reitan RM, Tucson AZ. Trail making test: manual for administration and scoring: Reitan Neuropsychology Laboratory; 1992.
   Google Scholar
• Reitan RM. Validity of the trail making test as an indicator of organic brain damage. Percept Mot Skills. 1958;8:271–276. doi: 10.2466/pms.1958.8.3.271
   Google Scholar
• Rey A. L’examen Clinique en Psychologie. Oxford: Presses Universitaries De France; 1958.
   Google Scholar
• Schmidt M. Rey auditory and verbal learning test: a handbook. Los Angeles (CA): Western Psychological Services; 1996.
   Google Scholar
• Wechsler D. A standardized memory scale for clinical use. J Psychol. 1945;19:87–95. doi: 10.1080/00223980.1945.9917223
   Web of Science ®Google Scholar
• Wechsler D. The Wechsler memory scale-fourth edition (WMS-IV). San Antonio (TX): Pearson Assessments; 2009.
   Google Scholar
• Stroop JR. Studies of interference in serial verbal reactions. J Exp Psychol. 1935;18:643–662. doi: 10.1037/h0054651
   Google Scholar
• Ekman P, Friesen WV. Manual for the facial action code. Palo Alto (CA): Consulting Psychologist Press; 1978.
   Google Scholar
• Saka MC, Atbaşoğlu EC. Şizofreni Epidemiyolojisi. Şizofreni ve Diğer Psikotik Bozukluklar [Epidemiology of schizophrenia. Schizophrenia and other psychotic disorders]. Ankara: Türkiye Psikiyatri Derneği Yayınları [Ankara: Turkey Psychiatric Association Publications]; 2007. p. 13–28.
   Google Scholar
• Kohler CG, Walker JB, Martin EA, et al. Facial emotion perception in schizophrenia: a meta-analytic review. Schizophr Bull. 2010;36:1009–1019. doi: 10.1093/schbul/sbn192
   PubMed Web of Science ®Google Scholar
• Suslow T, Roestel C, Ohrmann P, et al. Detection of facial expressions of emotions in schizophrenia. Schizophr Res. 2003;64:137–145. doi: 10.1016/S0920-9964(03)00061-6
   Web of Science ®Google Scholar
• Goff DC, Hill M, Barch D. The treatment of cognitive impairment in schizophrenia. Pharmacol Biochem Behav. 2011;99:245–253. doi: 10.1016/j.pbb.2010.11.009
   PubMed Web of Science ®Google Scholar
• Gallese V. The roots of empathy: the shared manifold hypothesis and the neural basis of intersubjectivity. Psychopathol. 2003;36:171–180. doi: 10.1159/000072786
   PubMed Web of Science ®Google Scholar
• Sachs G, Steger-Wuchse D, Kryspin-Exner I, et al. Facial recognition deficits and cognition in schizophrenia. Schizophr Res. 2004;68:27–35. doi: 10.1016/S0920-9964(03)00131-2
   PubMed Web of Science ®Google Scholar
• Mandal MK, Jain A, Haque-Nizamie S, et al. Generality and specificity of emotion-recognition deficit in schizophrenic patients with positive and negative symptoms. Psychiatry Res. 1999;87:39–46. doi: 10.1016/S0165-1781(99)00047-5
   PubMed Web of Science ®Google Scholar
• Johnston PJ, Enticott PG, Mayes AK, et al. Symptom correlates of static and dynamic facial affect processing in schizophrenia: evidence of a double dissociation? Schizophr Bull. 2010;36:680–687. doi: 10.1093/schbul/sbn136
   PubMed Web of Science ®Google Scholar
• Sasayama D, Hattori K, Teraishi T, et al. Negative correlation between cerebrospinal fluid oxytocin levels and negative symptoms of male patients with schizophrenia. Schizophr Res. 2012;139:201–206. doi: 10.1016/j.schres.2012.06.016
   PubMed Web of Science ®Google Scholar
• Jobst A, Dehning S, Ruf S, et al. Oxytocin and vasopressin levels are decreased in the plasma of male schizophrenia patients. Acta Neuropsychiatr. 2014;26:347–355. doi: 10.1017/neu.2014.20
   PubMed Web of Science ®Google Scholar
• Aydin O, Lysaker PH, Balikci K, et al. Associations of oxytocin and vasopressin plasma levels with neurocognitive, social cognitive and meta cognitive function in schizophrenia. Psychiatry Res. 2018;270:1010–1016. doi: 10.1016/j.psychres.2018.03.048
   PubMed Web of Science ®Google Scholar
• Iager AC, Kirch DG, Bigelow LB, et al. Treatment of schizophrenia with a vasopressin analogue. Am J Psychiatry. 1986;143:375–377. doi: 10.1176/ajp.143.3.375
   PubMed Web of Science ®Google Scholar
• Guzel D, Yazici AB, Pek TM, et al. Atrial natriuretic peptide and posterior pituitary neurohormone changes in patients with acute schizophrenia. Neuropsychiatr Dis Treat. 2018;14:1855–1860. doi: 10.2147/NDT.S169619
   Web of Science ®Google Scholar
• Feifel D, Macdonald K, Cobb P, et al. Adjunctive intranasal oxytocin improves verbal memory in people with schizophrenia. Schizophr Res. 2012;139:207–210. doi: 10.1016/j.schres.2012.05.018
   PubMed Web of Science ®Google Scholar
• van Londen L, Kerkhof GA, van den Berg F, et al. Plasma arginine vasopressin and motor activity in major depression. Biol Psychiatry. 1998;43:196–204. doi: 10.1016/S0006-3223(97)80433-7
   PubMed Web of Science ®Google Scholar
• Buresova O, Skopkova J. Vasopressin analogues and spatial short-term memory in rats. Pept. 1980;1:261–263. doi: 10.1016/0196-9781(80)90064-9
   Web of Science ®Google Scholar
• Morris R. Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods. 1984;11:47–60. doi: 10.1016/0165-0270(84)90007-4
   PubMed Web of Science ®Google Scholar
• Strauss GP, Chapman HC, Keller WR, et al. Endogenous oxytocin levels are associated with impaired social cognition and neurocognition in schizophrenia. J Psychiatr Res. 2019;112:38–43. doi:10.1016/j.jpsychires.2019.02.017.
   Web of Science ®Google Scholar
• Pedersen CA, Gibson CM, Rau SW, et al. Intranasal oxytocin reduces psychotic symptoms and improves theory of mind and social perception in schizophrenia. Schizophr Res. 2011;132:50–53. doi: 10.1016/j.schres.2011.07.027
   PubMed Web of Science ®Google Scholar
• De Coster L, Matholan DH, Woolley JD. Neural and behavioral effects of oxytocin administration during theory of mind in schizophrenia and controls: a randomized control trial. Neuropsychopharmacol. 2019 May 18. doi:10.1038/s41386-019-0417-5. [Epub ahead of print]
   Web of Science ®Google Scholar
• Jarskog LF, Pedersen CA, Johnson JL, et al. A 12-week randomized controlled trial of twice-daily intranasal oxytocin for social cognitive deficits in people with schizophrenia. Schizophr Res. 2017;185:88–95. doi: 10.1016/j.schres.2017.01.008
   PubMed Web of Science ®Google Scholar
• Strauss GP, Granholm E, Holden JL, et al. The effects of combined oxytocin and cognitive behavioral social skills training on social cognition in schizophrenia. Psychol Med. 2019:49:1731–1739. doi: 10.1017/S0033291718002465
   Web of Science ®Google Scholar
• Rubin LH, Carter CS, Bishop JR, et al. Reduced levels of vasopressin and reduced behavioral modulation of oxytocin in psychotic disorders. Schizophr Bull. 2014;40:1374–1384. doi: 10.1093/schbul/sbu027
   PubMed Web of Science ®Google Scholar
• Lee MR, Wehring HJ, McMahon RP, et al. The effect of intranasal oxytocin on measures of social cognition in schizophrenia: a negative report. J Psychiatr Brain Sci. 2019;4(1):e190001.
   Google Scholar
• Vadas L, Bloch B, Levin R, et al. Sex-specific effect of intranasal vasopressin, but not oxytocin, on emotional recognition and perception in schizophrenia patients. Eur Psychiatry. 2017;41:S387–S3S8. doi: 10.1016/j.eurpsy.2017.02.430
   Web of Science ®Google Scholar
• Goldman R, Bates J, Bilder R, et al. The effects of clozapine and haldol on memory functioning in treatment refractory schizophrenics. Schizophr Res. 1996;18:221. doi: 10.1016/0920-9964(96)85680-5
   Web of Science ®Google Scholar
• Raskind MA, Courtney N, Murburg MM, et al. Antipsychotic drugs and plasma vasopressin in normals and acute schizophrenic patients. Biol Psychiatry. 1987;22:453–462. doi: 10.1016/0006-3223(87)90167-3
   Web of Science ®Google Scholar
• Yıldırım EA, Essizoğlu A, Mengi M, et al. Endojen bir anksiyolitik olarak atrial natriüretik peptid. Yeni Symposium. 2012;50:3–12.
   Google Scholar